

# OPIOIDS ER

## PRIOR AUTHORIZATION/MEDICAL NECESSITY DETERMINATION

### PRESCRIBER FAX FORM

**ONLY the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.**

**Incomplete forms will be returned for additional information.** Start saving time today by filling out this prior authorization form electronically. Visit [www.NaviNet.net/hzdpa](http://www.NaviNet.net/hzdpa) to register and then begin using this free service as part of your existing NaviNet account.

#### PATIENT AND INSURANCE INFORMATION

Today's Date: \_\_\_\_\_

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
Patient Address:		City, State, Zip:	Patient Telephone:
Member ID Number:		Group Number:	

#### PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

#### PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient diagnosis:

Chronic cancer pain due to active malignancy

Chronic non-cancer pain

Other (ICD code and description): \_\_\_\_\_

Medication requested: \_\_\_\_\_ Strength: \_\_\_\_\_

Dosing schedule: \_\_\_\_\_ Quantity per month: \_\_\_\_\_

**All requests:**

- Is the patient currently taking the requested agent? .....  Yes  No  
If yes, is the patient at risk if therapy is changed? .....  Yes  No
- Is the patient eligible for hospice care? .....  Yes  No
- Has the prescriber counseled the patient on how to safely dispose of left-over medications to reduce the risk of diversion? .....  Yes  No
- Does the patient have any FDA labeled contraindications to the requested agent? .....  Yes  No
- Is the patient concurrently taking a buprenorphine containing agent for opioid dependence treatment? .....  Yes  No  
If yes, is there information to support concurrent use of opioids with a buprenorphine containing agent for opioid dependence treatment? .....  Yes  No
- Please explain why the patient needs the requested quantity (dose) for the requested indication: \_\_\_\_\_
- Can the requested quantity (dose) be achieved with a lower quantity of a higher strength that does not exceed the quantity limit? .....  Yes  No  
If no, please explain why the requested dose cannot be optimized: \_\_\_\_\_

**Chronic non-cancer pain requests:**

- Are there medical records showing a formal, consultative evaluation including diagnosis and a complete medical history which includes previous and current pharmacological and non-pharmacological therapy? **Please note, medical records are required.** .....  Yes  No
- Is the requested agent being prescribed as an as-needed (prn) analgesic? .....  Yes  No
- Has the patient had a trial of at least 7 days of an immediate-acting opioid? .....  Yes  No  
If no, does the patient have a documented intolerance, FDA labeled contraindication(s), or hypersensitivity to immediate-acting opioids? .....  Yes  No

**Please continue on the next page.**

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
-----------------------	-------	----	-------------------

11. Are there medical records showing the prescriber has a patient-specific pain management plan on file for the patient? **Please note, medical records are required.** .....  Yes  No
12. Has the prescriber confirmed that the patient is not diverting the requested agent, according to the patient's records in the state's prescription drug monitoring program (PDMP), if applicable? .....  Yes  No
13. Will the prescriber be conducting random urine drug screenings? .....  Yes  No
14. Are there medical records showing the patient's current medication list? **Please note, medical records are required.** .....  Yes  No
15. Is the patient's total MME > 90 mg per day? .....  Yes  No  
 If yes, is there information about a treatment plan to reduce the MME to < 90 mg per day? .....  Yes  No  
 If yes, please explain: \_\_\_\_\_
- \_\_\_\_\_
- If yes, is there information as to why the patient cannot tolerate a reduction in the MME? .....  Yes  No  
 If yes, please explain: \_\_\_\_\_
- \_\_\_\_\_
16. Is the patient on multiple long-acting opioid formulations chronically? .....  Yes  No
17. Has the prescriber formally evaluated the patient's risk of overdose and offered naloxone if applicable? .....  Yes  No

**Oxycontin (brand) and oxycodone ER (generic) requests:**

18. Are there medical records showing the patient has tried and failed Xtampza? **Please note, medical records are required.** .....  Yes  No  
 If no, are there medical records showing the patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to Xtampza? **Please note, medical records are required.** .....  Yes  No

**Tramadol or tapentadol requests:**

19. If the patient is outside the FDA approved age range, is the patient currently stabilized on the requested agent and has been on therapy for a minimum of 90 days and discontinuing treatment could potentially cause harm or a health risk? .....  Yes  No

**Renewal requests:**

20. Is the patient undergoing treatment for chronic non-cancer pain? .....  Yes  No  
 If yes, is the requested agent being prescribed as an as-needed (prn) analgesic? .....  Yes  No  
 If yes, has the prescriber confirmed that the patient is not diverting the requested agent, according to the patient's records in the state's prescription drug monitoring program (PDMP), if applicable? .....  Yes  No  
 If yes, will the prescriber be conducting random urine drug screens? .....  Yes  No  
 If yes, is the patient on multiple long-acting opioid formulations chronically? .....  Yes  No  
 If yes, has the prescriber formally evaluated the patient's risk of overdose and offered naloxone, if applicable? .....  Yes  No

**Please fax or mail this form to:**

Horizon Blue Cross Blue Shield of New Jersey  
 c/o Prime Therapeutics LLC, Clinical Review Department  
 2900 Ames Crossing Road  
 Eagan, MN 55121

**TOLL FREE**

**Fax: 877.897.8808 Phone: 888.214.1784**

**CONFIDENTIALITY NOTICE:** This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 888.214.1784, and return the original message to Horizon Blue Cross Blue Shield of New Jersey c/o Prime Therapeutics via U.S. Mail. Thank you for your cooperation.